Gilead Sciences (GILD) has been one of the most searched-for stocks ... While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' ...

Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Gilead Sciences Inc. closed $1.29 short of its 52-week high ($98.32), which the company reached on November 7th. Supported by world-class markets data from Dow Jones and FactSet, and partnering ...

An ex-Gilead worker who says he was illegally fired for refusing to steal confidential material isn’t protected by a ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $96.57 which represents a decrease of $-1.33 or -1.36% from the prior close of $97.9. The stock opened at $96.05 and ...

Gilead Sciences ( (GILD) ) has released its Q3 earnings. Here is a breakdown of the information Gilead Sciences presented to its investors.

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings estimates and raised its guidance, boosted by demand for its HIV and ...

2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2024 results of operations. SANTA MONICA, Calif., November 05, 2024--Kite, a Gilead Company (Nasdaq: GILD), will share ...

Gilead Sciences, Inc.'s (NASDAQ:GILD) stock was strong despite it releasing a soft earnings report last week. However, we ...

November 13, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full ...